Welcome!

.NET Authors: Elizabeth White, ChandraShekar Dattatreya, Trevor Parsons, Peter Silva, Yeshim Deniz

News Feed Item

Synthesis Polypeptide Drug Market (Global and China) Research Report for 2012

DALLAS, November 30, 2012 /PRNewswire/ --

RnRMarketResearch.com adds new market research report "2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry" to its store.

2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry is a professional and in-depth research report on China Synthesis Polypeptide Drug market. The report introduces Synthesis Polypeptide Drug with basic information including definition, classification, application, industry chain structure, industry overview and more. The research covers international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Synthesis Polypeptide Drug industry policy and plan, Synthesis Polypeptide Drug product specification, manufacturing process, product cost structure, etc. Statistics of China's key manufacturers of Synthesis Polypeptide Drug with their capacity production cost price profit production value gross margin and other details are also covered. In addition to the above said information, the study also presents products and their customers, application, capacity, market position, company contact information and other related information of these companies. The report also covers all these manufacturers' data and lists China Synthesis Polypeptide Drug capacity production capacity market share production market share supply demand shortage import export consumption etc data statistics, and then introduced China Synthesis Polypeptide Drug 2009-2013 capacity production price cost profit production value gross margin etc information. And also lists Synthesis Polypeptide Drug upstream raw materials equipments and Sharp Solarnstream clients alternative products survey analysis and Synthesis Polypeptide Drug marketing channels industry development trend and proposals. In the end, this report introduced Synthesis Polypeptide Drug new project SWOT analysis Investment feasibility analysis investment return analysis and also give related research conclusions and development trend analysis of China Synthesis Polypeptide Drug industry. In a word, it was a depth research report on China Synthesis Polypeptide Drug industry. And thanks to the support and assistance from Synthesis Polypeptide Drug industry chain related technical experts and marketing engineers during Research Team survey and interviews.

Buy your copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=57872

Table of Contents for the report "2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry" cover:

Chapter One Synthesis Polypeptide Drug Industry Overview    1
1.1 Synthesis Polypeptide Drug Definition    1
1.2 Synthesis Polypeptide Drug Classification and Application    3
1.3 Professional Terms Interpretation    8
1.4 Synthesis Polypeptide Drug Industry Chain Structure    12
1.5 Synthesis Polypeptide Drug Industry Overview    14
Chapter Two Synthesis Polypeptide Drug International and China Market Analysis    16
2.1 Synthesis Polypeptide Drug Industry International Market Analysis    16
2.1.1 Synthesis Polypeptide Drug International Market Development History    16
2.1.2 Synthesis Polypeptide Drug Product and Technology Developments    18
2.1.3 Synthesis Polypeptide Drug Competitive Landscape Analysis    25
2.1.4 Synthesis Polypeptide Drug International Key Countries Development Status    28
2.1.5 Synthesis Polypeptide Drug International Market Development Trend    30
2.2 Synthesis Polypeptide Drug China Market Analysis    33
2.2.1 Synthesis Polypeptide Drug China Market Development History    33
2.2.2 Synthesis Polypeptide Drug Product and Technology Developments    33
2.2.3 Synthesis Polypeptide Drug Competitive Landscape Analysis    35
2.2.4 Synthesis Polypeptide Drug China Key Regions Development Status    37
2.2.5 Synthesis Polypeptide Drug China Market Development Trend    37
2.3 Synthesis Polypeptide Drug International and China Market Comparison Analysis    42
Chapter Three Major Synthesis Polypeptide Drug Analysis    43
3.1 Immunity Regulating Medicine (Allergy Infection and Immune)    43
3.1.1 Glatiramer Injection (Glatiramer Acetate)    43
3.1.2 Thymalfasin for Injection    46
3.1.3 Thymopentin Injection    49
3.1.4 Thymopetidum Injection    53
3.1.5 Summary    55
3.2 Digestive System Drugs (Gastrointestinal Type)    57
3.2.1 Octreotide Acetate Injection    57
3.2.2 Somatostatin for Injection    61
3.3 Bone and Connective Tissue Types (Thyroid hormones Drug)    66
3.3.1 Salmon Calcitonin Injection    67
3.3.2 Elcatonin Injection    70
3.3.4 TerfparaLide Injectlon    72
3.4 Gynecologic or Obstetric Drug    76
3.4.1 Oxytocin Injection    76
3.4.2 Carbetocin Injection    81
3.4.3 Acetate Atosiban Injection    83
3.5 Tumor Drug (hCG)    86
3.5.1 Leuprorelin Acetate Microspheres for Injection    87
3.5.2 Goserelin Acetate    89
3.5.3 Triptorelin Acetate Injection    92
3.5.4 Chorionic Gonadotrophin for Injection    95
3.6 Urinary System Drug (Diabetes Insipidus)    98
3.6.1 Desmopressin Acetate Injection    98
3.6.2 Terlipressin for Injection    101
3.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents)    105
3.7.1 Biosynthetic Glucagon for Injection    105
3.7.2 Exenatide Injection    106
Chapter Four Synthesis Polypeptide Drug Development Environmental Analysis    109
4.1 China's Macroeconomic Environment Analysis    109
4.1.1 China GDP Analysis    109
4.1.2 China CPI Analysis    111
4.2 European Economic Environmental Analysis and Impact    113
4.3 United States Economic Environmental Analysis and Impact    116
4.4 Japan Economic Environmental Analysis and Impact    119
4.5 Global Economic Environmental Analysis and Impact    120
4.5.1 Global Economic Environmental Analysis    120
4.5.2 Global Economic Influence    121
Chapter Five Synthesis Polypeptide Drug Development Policy and Plan    121
5.1 China Government Policy and Development Plan    121
5.2 Industry Policy and Standard    122
5.3 Technical Standard    125
5.4 Technology Replacement and R&D Trends    126
5.5 Hotspots and Influence    127
Chapter Six Synthesis Polypeptide Drug Manufacturing Process and Cost Structure    132
6.1 Synthesis Polypeptide Drug Manufacturing Process Overview    132
6.2 Synthesis Polypeptide Drug Manufacturing Process Analysis    135
6.3 Synthesis Polypeptide Drug Cost Structure Analysis    138
Chapter Seven 2009-2013 Synthesis Polypeptide Drug Productions Supply Sales Demand Market Status and Forecast    140
7.1 2009-2013 Synthesis Polypeptide Drug Capacity Production Overview    140
7.1.1 2009-2013 Global and China Synthesis Polypeptide Drug Capacity Production    140
7.1.2 2009-2013 Synthesis Polypeptide Drug Production Market Share    146
7.1.3 2009-2013 Synthesis Polypeptide Drug Demand Overview    152
7.1.4 2009-2013 Synthesis Polypeptide Drug Supply Demand and Shortage    152
7.1.5 2009-2013 Synthesis Polypeptide Drug Production Import Export Consumption    153
7.1.6 2009-2013 Synthesis Polypeptide Drug Cost Price Production Value Gross Margin    154
7.2 Different Type Synthesis Polypeptide Drug Sales and Market Scale Analysis    156
7.2.1Thymopentin Injection    156
7.2.2 Thymalfasin Injection    158
7.2.3 Calcitonin Injection    159
7.2.4 Somatostatin for Injection    161
7.2.5Octreotide Acetate Injection    162
7.2.6 Desmopressin Acetate Injection    163
7.3 Synthesis Polypeptide Drug Market Summary    165
Chapter Eight Synthesis Polypeptide Drug Key Manufacturers (Company Profiles)   170
8.1 Novartis    170
8.2 Merck Serono    176
8.3 Ferring Pharmaceuticals    181
8.4 Ipsen PHarma Biotech    188
8.5 Lilly    191
8.6 Asahi Kasei    195
8.7 AstraZeneca    199
8.8 SciClone Pharmaceuticals    203
8.9 Takeda    206
8.10 HYBIO Pharmaceutical Co.,Ltd (Shenzhen Stock:300199)    210
8.11 Hainan Zhonghe Pharmaceutical Co.,Ltd    215
8.12 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd    219
8.13 Beijing Yingu Century Pharmaceutical Co.,Ltd (Beijing Shiqiao Bio-Pharmaceutical Co.,Ltd)    224
8.14 Hainan Shuangcheng Pharmaceuticals Co.,Ltd    227
8.15 Livzon Pharmaceuticals Co.,Ltd (Livzon:000513)    234
8.16 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd    238
8.17 Chengdu Tiantaishan Pharmaceutical Co.,Ltd    242
8.18 Beijing Shuanglu Pharmaceutical Co.,Ltd    250
8.19 Yangzijiang Pharmaceutical Co.,Ltd    257
8.20 Changzhou Siyao Pharmaceutical Co.,Ltd    262
Chapter Nine Up and Down Stream Industry Analysis and Influence    267
9.1 Upstream Raw Materials Price Analysis and Influence    267
9.1 Upstream Equipments Market Analysis and Influence    269
9.3 Downstream Demand Analysis and Influence    270
9.4 Industry Policy Analysis and Influence    271
Chapter Ten Synthesis Polypeptide Drug Marketing Channels Analysis    272
10.1 Synthesis Polypeptide Drug Marketing Channels Status    272
10.1.1 Drugs Marketing Channel Developemnt History    272
10.1.1 Prescription Drug Marketing Development Status    273
10.2 Synthesis Polypeptide Drug Marketing Channels Management    274
10.3 Synthesis Polypeptide Drug Marketing Channels Establishment    275
10.4 Synthesis Polypeptide Drug Marketing Channels Development Trend    276
Chapter Eleven Synthesis Polypeptide Drug Industry Development Trend    278
11.1 2012-2016 Synthesis Polypeptide Drug Industry Development Trend    278
11.2 2012-2016 Market Potential Forecast    279
11.3 2012-2016 R&D Trend    280
11.3.1Polypeptide Drug Technical Development Status    280
11.3.2 Polypeptide Drug and Health Care Products Research and Manufacturing Overview    282
11.3.3 China Polypeptide Drug Development Direction and Prospect    283
11.4 2012-2016 Marketing Channels Change Trend    285
14.4.1 Prescription Drug Marketing Channels Change Trend    285
14.4.2 Prescription Drug Sales Method Five Trend    286
11.5 2012-2016 Competition Pattern Development Trends    288
Chapter Twelve Synthesis Polypeptide Drug Industry Development Proposals    289
12.1 Macroeconomic Development Countermeasures    289
12.2 New Firms Enter Market Strategy    290
12.2.1 New Business Entry Barriers    290
12.2.2 New Corporate Strategy    290
12.3 New Project Investment Proposal    293
12.4 Marketing Channel Strategy Proposals    294
12.5 Competitive Environment Strategy Proposals    296
12.5.1 Competitive Environment Analysis    296
12.5.2 Strategy Proposals    297
Chapter Thirteen Synthesis Polypeptide Drug New Project Investment Feasibility Analysis    300
13.1 Synthesis Polypeptide Drug Project SWOT Analysis    300
13.2 Synthesis Polypeptide Drug New Project Investment Feasibility Analysis    302
13.2.1 Buildings    302
13.2.2 Investment    303
13.2.3 Project Schedule    303
13.2.4 Project Investment Return and Feasibility Analysis    304
Chapter Fourteen Synthesis Polypeptide Drug Industry Research Conclusions    304

 

List Of Tables and Figures

Figure Synthesis Polypeptide Process Flow    1
Figure Synthesis Polypeptide Drug Picture-Thymopentin Injection    2
Figure Polypeptide Applications on Health Care Food and Cosmetics Fields    4
Figure Polypeptide Drug Manufacturing Process Method    4
Table Synthesis Polypeptide Drug Classification and Application List    5
Table Synthesis Polypeptide Drug Product Name Use and Annual Sales Revenue (USD) List    6
Table Listed Polypeptide Drug Name Type Indication    6
Figure Pharmaceutical Industry Value Chain Structure    12
Figure Pharmaceutical Industry Industry Chain Structure    12
Figure Synthesis Polypeptide Drug Industry Chain Structure    13
Figure Synthesis Polypeptide Drug Industrialization System    13
Figure 2000-2011 China Pharmaceutical Industry Sales Revenue and Total Profit (100 Million RMB) and Growth Rate    14
Figure 2007-2015 China Synthesis Polypeptide Drug Market Scale (100 Million RMB) and Growth Rate    15
Figure DNA Transcribed into RNA Diagram    17
Figure RNA Translated into Polypeptide Chains Molecular Diagram    18
Table Polypeptide Drug Three Manufacturing Methods    19
Figure 1984 Chemistry Nobel Prize Winner Robert Bruce Merrifield    20
Figure Polypeptide Solid Phase Synthesis Principle    20
Figure Solid Phase Polypeptide Synthesis    21
Figure United States CS Three Channel Full Automatic Polypeptide Synthetic Instrument    22
Figure Homemade CS136 Model Research Polypeptide Synthetic Instrument    23
Figure Large Scale Liquid Phase Synthesis of Polypeptide    24
Figure Thin Film Evaporator (for perishable goods Concentration)    24
Table Global 2008 Revenue More than 1 Billion Polypeptide Drug Brands List    25
Table Some Listed Polypeptide Drug Indication Classification    26
Figure Listed Polypeptide Drug Indication Classification Market Share    26
Figure 2004-2014 Global Pharmaceutical Sales Revenue (Billion USD) and Growth Rate    30
Figure 2009-2013 International Synthesis Polypeptide Drug Market Scale (100 Million RMB) and Growth Rate    31
Table 2011 Some Polypeptide Drug Global Sales Revenue (100 Million USD)    31
Figure Each Year Enter Clinical Research Polypeptide Drug Quantity (Piece)    32
Table 17 Emerging Pharmaceutical Market Sizes (Billion USD)    38
Figure 2007-2015 China Pharmaceutical Sales Revenue (100 Million USD)    39
Figure 2009-2015 China Polypeptide Drug Market Scale (100 Million RMB) and Growth Rate    39
Figure 2009-2015 China Chemical Synthesis Polypeptide Drug Market Scale (100 Million RMB) and Growth Rate    40
Figure 2009-2015 China Chemical Synthesis Polypeptide Drug Market Scale (100 Million RMB) and Proportion of China Total Polypeptide Drug Market Scale    41
Figure 2007-2009 China Chemical Synthesis Polypeptide Drug Types Market Share    41
Table Copaxone Neuron Structure Diagram    44
Table Thymalfasin for Injection (Thymalfasin a1) Suppliers List    48
Table 2010 Thymalfasin for Injection Key Products Price (RMB/Piece) List    49
Table Some Thymopentin Injection Suppliers List    51
Table Thymopentin Injection Hospital Purchase Price (RMB/Piece) List    52
Table Thymopetidum Injection Thymopentin Injection Thymalfasin Injection Comparison    56
Table Octreotide Acetate Injection Key Suppliers List    59
Table 2012 Hebei Province Octreotide Acetate Injection Bid Price List    60
Tale Somatostatin for Injection Key Suppliers List    64
Table Somatostatin for Injection Key Products Hospital Average Purchae Price List    64
Table 2012 Hebei Province Somatostatin for Injection Key Suppliers List    65
Table Salmon Calcitonin Injection Suppliers List    69
Table Salmon Calcitonin Injection/Nasal Spray Products Hospital Purchase Price List    69
Table Salmon Calcitonin Injection/Nasal spray Products Retail Price List    70
Table Elcatonin Injection Key Suppliers and Product Selling Price List    72
Figure TerfparaLide Injectlon-Forsteo Injection Pen Parts    75
Table 2011Q1 China Some Aproved New Drug Number, Specifications Suppliers and Indication    76
Table 2012 New Add Key Monitoring Drug Table--TerfparaLide Injectlon    76
Table Oxytocin Injection Key Suppliers List    78
Table Oxytocin Injection Suppliers Products Models List    80
Table Carbetocin Injection Suppliers List    83
Table Acetate Atosiban Injection Supplier Product Specification Price List    85
Table Leuprorelin Acetate Microspheres for Injection Suppliers Product Specification Price List    88
Table Triptorelin Acetate Injection Suppliers Product Specification Price List    94
Table Chorionic Gonadotrophin for Injection Suppliers Product Specifications List    97
Table 2011 Some Hormone Drugs Independent Pricing and Uniform Pricing Comparison    98
Table Desmopressin Acetate Injection Key Suppliers List    100
Table Desmopressin Acetate Injection Key Suppliers Forms Product Specifications and Bid Price List    101
Table Terlipressin for Injection Key Brands Manufacturers and Retail Prices    104
Table Biosynthetic Glucagon for Injection Suppliers and Retail Prices List    106
Table Exenatide Suppliers Product Specifications Retail Prices List    109
Figure 2007-2015 China Medical Industry Total Production Value (100 Million RMB) and Growth Rate    110
Table 2006-2011 China GDP (1000 Million RMB) and Growth Rate    110
Figure 2007-2011 China Medical Industry Total Value and Its Proportion of China Total GDP    111
Figure 2007-2015 China Individual Medical Expenditure (RMB)    112
Figure 2007-2015 China Health Expenditure Per Capita and National Medical Expenditure Comparison    112
Figure 2011-2016 China Population Growth and Aging Condition    113
Figure 2006-2011 Europe Several Countries PMI Trend    114
Figure United States CPI and PCE Growth Comparison    117
Figure United States Private Savings Rate Change and Net Export /GDP Proportion Change Trend    118
Figure United States Public Debt and Deficit Proportion of GDP    119
Figure Japan GDP and CPI Growth Rate Comparison    119
Figure 2009-2011 China Health Capital Investment (100 Million RMB)    122
Table China Pharmaceutical Industry All major Departments and Regulatory Functions    122
Table Pharmaceutical Industry main Laws and Regulations and Policies    125
Table 2009-2012 China Medical and Health System Reform Important Policy    128
Table 2009-2012 China Related Pharmaceutical Product Quality Supervision Policy    129
Table 2008-2012 China Development and Reform Commission Policy on Drug Price Management Policies    130
Figure PTIPolypeptide Synthetic Instruments Picture    133
Table Synthesis Polypeptide Drug Technology Processes List    133
Figure Polypeptide Pharmaceutical Raw Materials Manufacturing Process Flow    135
Figure Freeze Dried Powder Injection Manufacturing Process Flow    136
Figure Small Capacity Injection Manufacturing Process Flow    136
Figure Thymalfasin API Manufacturing Process Flow    137
Figure Thymalfasin Injection Manufacturing Process Flow    138
Figure International Synthesis Polypeptide Drug Cost Structure    139
Table 2009-2011 China Synthesis Polypeptide Drug Cost Structure    139
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Capacity and Total Capacity (10K Piece) List    140
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Capacity Market Share List    140
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Production and Total Production (10K Piece) List    141
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Production Market Share List    141
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Capacity and Total Capacity (10K Piece) List    142
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Capacity Market Share List    142
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Production and Total Production (10K Piece) List    143
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Production Market Share List    143
Figure 2009-2013 Global Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    144
Table 2009-2013 Global Synthesis Polypeptide Drug Capacity Utilization Rate List    144
Figure 2009-2013 China Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    145
Table 2009-2013 China Synthesis Polypeptide Drug Capacity Utilization Rate List    145
Table 2009-2013 Key Manufacturers Synthesis Polypeptide Drug China Sales (10K Piece) Top20 List    146
Table 2009-2013 Key Manufacturers Synthesis Polypeptide Drug China Sales Top20 Market Share List    147
Table 2010 Key Manufacturers Synthesis Polypeptide Drug China Sales Revenue (100 Million RMB) Top10 List    147
Table 2008-2010 Key Manufacturers Synthesis Polypeptide Drug China Sales Revenue Top10 Market Share List    148
Figure 2011 Key Manufacturers Synthesis Polypeptide Drug China Sales Market Share    149
Figure 2012 Key Manufacturers Synthesis Polypeptide Drug China Sales TOP20 Market Share    150
Figure 2011 China Key Manufacturers Synthesis Polypeptide Drug Production Market Share    151
Figure 2012 China Key Manufacturers Synthesis Polypeptide Drug Production Market Share    151
Table 2009-2013 Global Synthesis Polypeptide Drug Demand (10K Piece) and Growth Rate    152
Table 2009-2013 China Synthesis Polypeptide Drug Demand (10K Piece) and Growth Rate    152
Table 2009-2013 China Synthesis Polypeptide Drug Supply Demand and Shortage (10K Piece)    153
Table 2009-2013 Nine Foreign Enterprises Synthesis Polypeptide Drug China Sales (10K Piece) List    153
Table 2009-2013 China Synthesis Polypeptide Drug Production Import Export Consumption (10K Piece) List    154
Table 2007-2009 China Synthesis Polypeptide Drug Price (RMB/Piece) Distribution    154
Table 2009-2011 Hainan Shuangcheng Pharmaceuticals Some Synthesis Polypeptide Drug Price Cost (RMB/Piece) Gross Margin List    155
Table 2009-2013 China Synthesis Polypeptide DrugProduction (10K Piece) Price Cost Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    155
Figure 2011 China Synthesis Polypeptide Drug Market Share by Different Type Drug    156
Figure 2008-2014 China Thymopentin Injection Market Scale (100 Million RMB) and Growth Rate    157
Figure 2008-2014 China Thymopentin Injection Sales (10K Piece) and Growth Rate    157
Figure 2008-2014 China Thymalfasin Injection Market Scale (100 Million RMB) and Growth Rate    158
Figure 2008-2014 China Thymalfasin Injection Sales (10K Piece) and Growth Rate    159
Figure 2008-2014 China Calcitonin Injection Market Scale (100 Million RMB) and Growth Rate    160
Figure 2008-2014 China Calcitonin Injection Sales (10K Piece) and Growth Rate    160
Figure 2008-2014 China Somatostatin for Injection Market Scale (100 Million RMB) and Growth Rate    161
Figure 2008-2014 China Somatostatin for Injection Sales (10K Piece) and Growth Rate    162
Figure 2008-2014 China Octreotide Acetate Injection Market Scale (100 Million RMB) and Growth Rate    163
Figure 2008-2014 China Octreotide Acetate Injection Sales (10K Piece) and Growth Rate    163
Figure 2008-2014 China Desmopressin Acetate Injection Market Scale (100 Million RMB) and Growth Rate    164
Figure 2008-2014 China Desmopressin Acetate Injection Sales (10K Piece) and Growth Rate    164
Table 2009-2011 China Chemical Synthesis Polypeptide Drug Injection Distribution List    165
Figure 2010 Global Polypeptide Drug Market Structure by Treatment Class    165
Table Research or Listed Polypeptide Drugs List    166
Figure 1990-2010 China Resident Three Types of Chronic Disease Prevalence (1/100K) Change Trend    167
Figure 2010 China Synthesis Polypeptide Drug Hospital Terminal Sales Market Share Distribution    168
Figure 2010 China Synthesis Polypeptide Drug Top10 Manufacturers Sales Revenue (100 Million RMB)    168
Figure China Synthesis Polypeptide Drug Prices Distribution    169
Figure Use Me-Too Model Developed Polypeptide Drug List    169
Table Novartis Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    170
Figure Novartis China Market Sales Synthesis Polypeptide Drug--Octreotide Acetate Injection    173
Figure Novartis China Market Sales Synthesis Polypeptide Drug--Somatostatin Acetate for Injection    173
Figure Novartis China Market Sales Synthesis Polypeptide Drug--salmon Calcitonin Nasal Spray    174
Table 2009-2013 Novartis Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    174
Figure 2009-2013 Novartis Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    175
Table Merck Serono Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    176
Figure Merck Serono Synthesis Polypeptide Drug--Recombinant Human Follitropin Alfa Solution for Injection    178
Figure Merck Serono Synthesis Polypeptide Drug--Somatostatin for Injection    179
Figure Merck Serono Synthesis Polypeptide Drug--Gonadorelin for Injection    179
Table 2009-2013 Merck Serono Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    180
Figure 2009-2013 Merck Serono Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    181
Table Ferring Pharmaceuticals Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    182
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Minirin    183
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Decapeptyl    184
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Pentasa    184
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Glypressin    185
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Octostim    186
Table 2009-2013 Ferring Pharmaceuticals Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    186
Figure 2009-2013 Ferring Pharmaceuticals Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    188
Table Ipsen PHarma Biotech Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    188
Figure Ipsen PHarma Biotech  Synthesis Polypeptide Drug--Triptorelin Acetate for Injection    190
Table 2009-2013 Ipsen PHarma Biotech Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    190
Figure 2009-2013 Ipsen PHarma Biotech Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    191
Table Lilly Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    192
Figure Lilly Some China Listed Synthesis Polypeptide Drug List    194
Table 2009-2013 Lilly Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    194
Figure 2009-2013 Lilly Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    195
Table Asahi Kasei Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    195
Figure Asahi Kasei Synthesis Polypeptide Drug--Elcatonin Injection    198
Table 2009-2013 Asahi Kasei Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    198
Figure 2009-2013 Asahi Kasei Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    199
Table AstraZeneca Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    199
Figure AstraZeneca China Selling Synthesis Polypeptide Drug-Goserelin Acetate Slow Release Implantation Agent    201
Table 2009-2013 Jiangsu AstraZeneca Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    202
Figure 2009-2013 Jiangsu AstraZeneca Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    203
Table SciClone Pharmaceuticals Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    204
Figure SciClone Pharmaceuticals Synthesis Polypeptide Drug-- Thymopetidum α1 Injection    205
Table 2009-2013 SciClone Pharmaceuticals Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    205
Figure 2009-2013 SciClone Pharmaceuticals Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    206
Table Takeda Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    206
Figure Takeda--Leuprorelin Acetate Microspheres for Injection    208
Table 2009-2013 Takeda Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    209
Figure 2009-2013 Takeda Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    209
Table HYBIO Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    210
Figure 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug    211
Table 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    213
Figure 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    215
Table Hainan Zhonghe Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    216
Figure Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug产品    217
Table 2009-2013 Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    217
Figure 2009-2013 Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    219
Table Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    219
Figure Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug-Thymalfasin Injection    221
Figure Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    222
Table 2009-2013 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    222
Figure 2009-2013 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    223
Table Beijing Yingu Century Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    224
Figure Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Salmon Calcitonin Nasal Spray    225
Figure Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    226
Table 2009-2013 Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    226
Figure 2009-2013 Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    227
Table Hainan Shuangcheng Pharmaceuticals Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    228
Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug--Thymalfasin Injection(基泰)    229
Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug-Somatostatin for Injection    231
Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection (双成可维)    232
Table 2009-2013 Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    233
Figure 2009-2013 Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    234
Table Livzon Pharmaceuticals Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    234
Figure Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug    236
Table 2009-2013 Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    236
Figure 2009-2013 Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    238
Table Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    239
Figure Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug--Thymopentin Injection    240
Figure Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug--Somatostatin for Injection    240
Table 2009-2013 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    241
Figure 2009-2013 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    242
Table Chengdu Tiantaishan Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    242
Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Somatostatin for Injection    244
Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    246
Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Octreotide Acetate Injection    247
Table 2009-2013 Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    248
Figure 2009-2013 Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    249
Table Beijing Shuanglu Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    250
Figure Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    251
Figure Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Salmon Calcitonin Injection    252
Table Beijing Shuanglu Pharmaceutical Co.,Ltd Thymopentin Injection Price List    253
Table 2009-2013 Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    256
Figure 2009-2013 Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    257
Table Yangzijiang Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    257
Figure Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Somatostatin for Injection    259
Figure Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    260
Table 2009-2013 Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    260
Figure 2009-2013 Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    261
Table Changzhou Siyao Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    262
Figure Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug List    264
Table Changzhou Siyao Pharmaceutical Co.,Ltd Chemical Pharmaceutical Raw Materials List    264
Table Changzhou Siyao Pharmaceutical Co.,Ltd Chemical Raw Materials Intermediates List    265
Table 2009-2013 Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    266
Figure 2009-2013 Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    266
Table Synthesis Polypeptide Drug Project Key Equipments and Price (10K RMB)    269
Table Synthesis Polypeptide Drug Project Equipments List and Price (10K RMB)    270
Table Drugs Manufacturing Enterprise Specialized Academic Promotion Organization Frame    276
Figure Synthesis Polypeptide Drug Industry Entry Barriers List    293
Table 2012 China Synthesis Polypeptide Drug New Project SWOT Analysis    300
Table 2012 China Synthesis Polypeptide Drug New Project Buildings List    302
Table 2012 China Synthesis Polypeptide Drug New Project Investments (10K RMB) List    303
Table Synthesis Polypeptide Drug New Project Investment Return and Feasibility Analysis    304

Browse more reports on the Pharmaceuticals Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals.

Explore newly published market research reports on other industries and for different geographies @ http://www.rnrmarketresearch.com/latest_reports.

About Us:

RnRMarketResearch.com (http://www.rnrmarketresearch.com/) is an online market research reports library of 175,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Contact:
Priyank Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected]
Explore more Industry reports @ http://www.marketreportsonline.com/.


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
Connected devices and the Internet of Things are getting significant momentum in 2014. In his session at Internet of @ThingsExpo, Jim Hunter, Chief Scientist & Technology Evangelist at Greenwave Systems, examined three key elements that together will drive mass adoption of the IoT before the end of 2015. The first element is the recent advent of robust open source protocols (like AllJoyn and WebRTC) that facilitate M2M communication. The second is broad availability of flexible, cost-effective storage designed to handle the massive surge in back-end data in a world where timely analytics is e...
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges. In his session at @ThingsExpo, Jeff Kaplan, Managing Director of THINKstrategies, will examine why IT must finally fulfill its role in support of its SBUs or face a new round of...
How do APIs and IoT relate? The answer is not as simple as merely adding an API on top of a dumb device, but rather about understanding the architectural patterns for implementing an IoT fabric. There are typically two or three trends: Exposing the device to a management framework Exposing that management framework to a business centric logic Exposing that business layer and data to end users. This last trend is the IoT stack, which involves a new shift in the separation of what stuff happens, where data lives and where the interface lies. For instance, it's a mix of architectural styles ...
We are reaching the end of the beginning with WebRTC, and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will want to use their existing identities, but these will have credentials already that are (hopefully) i...
Cultural, regulatory, environmental, political and economic (CREPE) conditions over the past decade are creating cross-industry solution spaces that require processes and technologies from both the Internet of Things (IoT), and Data Management and Analytics (DMA). These solution spaces are evolving into Sensor Analytics Ecosystems (SAE) that represent significant new opportunities for organizations of all types. Public Utilities throughout the world, providing electricity, natural gas and water, are pursuing SmartGrid initiatives that represent one of the more mature examples of SAE. We have s...
"Matrix is an ambitious open standard and implementation that's set up to break down the fragmentation problems that exist in IP messaging and VoIP communication," explained John Woolf, Technical Evangelist at Matrix, in this SYS-CON.tv interview at @ThingsExpo, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The Internet of Things will greatly expand the opportunities for data collection and new business models driven off of that data. In her session at @ThingsExpo, Esmeralda Swartz, CMO of MetraTech, discussed how for this to be effective you not only need to have infrastructure and operational models capable of utilizing this new phenomenon, but increasingly service providers will need to convince a skeptical public to participate. Get ready to show them the money!
One of the biggest challenges when developing connected devices is identifying user value and delivering it through successful user experiences. In his session at Internet of @ThingsExpo, Mike Kuniavsky, Principal Scientist, Innovation Services at PARC, described an IoT-specific approach to user experience design that combines approaches from interaction design, industrial design and service design to create experiences that go beyond simple connected gadgets to create lasting, multi-device experiences grounded in people's real needs and desires.
P2P RTC will impact the landscape of communications, shifting from traditional telephony style communications models to OTT (Over-The-Top) cloud assisted & PaaS (Platform as a Service) communication services. The P2P shift will impact many areas of our lives, from mobile communication, human interactive web services, RTC and telephony infrastructure, user federation, security and privacy implications, business costs, and scalability. In his session at @ThingsExpo, Robin Raymond, Chief Architect at Hookflash, will walk through the shifting landscape of traditional telephone and voice services ...
Scott Jenson leads a project called The Physical Web within the Chrome team at Google. Project members are working to take the scalability and openness of the web and use it to talk to the exponentially exploding range of smart devices. Nearly every company today working on the IoT comes up with the same basic solution: use my server and you'll be fine. But if we really believe there will be trillions of these devices, that just can't scale. We need a system that is open a scalable and by using the URL as a basic building block, we open this up and get the same resilience that the web enjoys.
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, discussed single-value, geo-spatial, and log time series data. By focusing on enterprise applications and the data center, he will use OpenTSDB as an example t...
The Domain Name Service (DNS) is one of the most important components in networking infrastructure, enabling users and services to access applications by translating URLs (names) into IP addresses (numbers). Because every icon and URL and all embedded content on a website requires a DNS lookup loading complex sites necessitates hundreds of DNS queries. In addition, as more internet-enabled ‘Things' get connected, people will rely on DNS to name and find their fridges, toasters and toilets. According to a recent IDG Research Services Survey this rate of traffic will only grow. What's driving t...
Enthusiasm for the Internet of Things has reached an all-time high. In 2013 alone, venture capitalists spent more than $1 billion dollars investing in the IoT space. With "smart" appliances and devices, IoT covers wearable smart devices, cloud services to hardware companies. Nest, a Google company, detects temperatures inside homes and automatically adjusts it by tracking its user's habit. These technologies are quickly developing and with it come challenges such as bridging infrastructure gaps, abiding by privacy concerns and making the concept a reality. These challenges can't be addressed w...
Explosive growth in connected devices. Enormous amounts of data for collection and analysis. Critical use of data for split-second decision making and actionable information. All three are factors in making the Internet of Things a reality. Yet, any one factor would have an IT organization pondering its infrastructure strategy. How should your organization enhance its IT framework to enable an Internet of Things implementation? In his session at Internet of @ThingsExpo, James Kirkland, Chief Architect for the Internet of Things and Intelligent Systems at Red Hat, described how to revolutioniz...
Bit6 today issued a challenge to the technology community implementing Web Real Time Communication (WebRTC). To leap beyond WebRTC’s significant limitations and fully leverage its underlying value to accelerate innovation, application developers need to consider the entire communications ecosystem.
The definition of IoT is not new, in fact it’s been around for over a decade. What has changed is the public's awareness that the technology we use on a daily basis has caught up on the vision of an always on, always connected world. If you look into the details of what comprises the IoT, you’ll see that it includes everything from cloud computing, Big Data analytics, “Things,” Web communication, applications, network, storage, etc. It is essentially including everything connected online from hardware to software, or as we like to say, it’s an Internet of many different things. The difference ...
Cloud Expo 2014 TV commercials will feature @ThingsExpo, which was launched in June, 2014 at New York City's Javits Center as the largest 'Internet of Things' event in the world.
SYS-CON Events announced today that Windstream, a leading provider of advanced network and cloud communications, has been named “Silver Sponsor” of SYS-CON's 16th International Cloud Expo®, which will take place on June 9–11, 2015, at the Javits Center in New York, NY. Windstream (Nasdaq: WIN), a FORTUNE 500 and S&P 500 company, is a leading provider of advanced network communications, including cloud computing and managed services, to businesses nationwide. The company also offers broadband, phone and digital TV services to consumers primarily in rural areas.
"There is a natural synchronization between the business models, the IoT is there to support ,” explained Brendan O'Brien, Co-founder and Chief Architect of Aria Systems, in this SYS-CON.tv interview at the 15th International Cloud Expo®, held Nov 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA.
The major cloud platforms defy a simple, side-by-side analysis. Each of the major IaaS public-cloud platforms offers their own unique strengths and functionality. Options for on-site private cloud are diverse as well, and must be designed and deployed while taking existing legacy architecture and infrastructure into account. Then the reality is that most enterprises are embarking on a hybrid cloud strategy and programs. In this Power Panel at 15th Cloud Expo (http://www.CloudComputingExpo.com), moderated by Ashar Baig, Research Director, Cloud, at Gigaom Research, Nate Gordon, Director of T...